| European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas G Raverot, P Burman, A McCormack, A Heaney, S Petersenn, V Popovic, ... European journal of endocrinology 178 (1), G1-G24, 2018 | 421 | 2018 |
| Consensus on diagnosis and management of Cushing's disease: a guideline update M Fleseriu, R Auchus, I Bancos, A Ben-Shlomo, J Bertherat, NR Biermasz, ... The lancet Diabetes & endocrinology 9 (12), 847-875, 2021 | 287 | 2021 |
| Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016 A McCormack, OM Dekkers, S Petersenn, V Popovic, J Trouillas, ... European journal of endocrinology 178 (3), 265-276, 2018 | 225 | 2018 |
| Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status AI McCormack, JAH Wass, AB Grossman European journal of clinical investigation 41 (10), 1133-1148, 2011 | 178 | 2011 |
| Low O6methylguanineDNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours AI McCormack, KL McDonald, AJ Gill, SJ Clark, MG Burt, KA Campbell, ... Clinical endocrinology 71 (2), 226-233, 2009 | 162 | 2009 |
| Using the ISBAR handover tool in junior medical officer handover: a study in an Australian tertiary hospital JE Thompson, LW Collett, MJ Langbart, NJ Purcell, SM Boyd, ... Postgraduate medical journal 87 (1027), 340-344, 2011 | 156 | 2011 |
| European Society of Endocrinology. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas G Raverot, P Burman, A McCormack, A Heaney, S Petersenn, V Popovic, ... Eur J Endocrinol 178 (1), G1-G24, 2018 | 121 | 2018 |
| Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases M Losa, E Mazza, MR Terreni, A McCormack, AJ Gill, M Motta, MG Cangi, ... European Journal of Endocrinology 163 (6), 843-851, 2010 | 109 | 2010 |
| Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic—an international perspective M Fleseriu, M Buchfelder, JS Cetas, PK Fazeli, SM Mallea-Gil, M Gurnell, ... Pituitary 23 (4), 327-337, 2020 | 61 | 2020 |
| Aggressive pituitary tumours and carcinomas: two sides of the same coin? J Trouillas, P Burman, A McCormack, S Petersenn, V Popovic, O Dekkers, ... European journal of endocrinology 178 (6), C7-C9, 2018 | 57 | 2018 |
| Outcomes of pituitary surgery for Cushing’s disease: a systematic review and meta-analysis A Stroud, P Dhaliwal, R Alvarado, MJ Winder, BP Jonker, JW Grayson, ... Pituitary 23 (5), 595-609, 2020 | 53 | 2020 |
| Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors SMC De Sousa, J Baranoff, RL Rushworth, J Butler, J Sorbello, J Vorster, ... The Journal of Clinical Endocrinology & Metabolism 105 (3), e108-e118, 2020 | 46 | 2020 |
| MANAGEMENT OF ENDOCRINE DISEASE: Does gender matter in the management of acromegaly? NF Lenders, AI McCormack, KKY Ho European Journal of Endocrinology 182 (5), R67-R82, 2020 | 45 | 2020 |
| Pituitary hyperplasia: case series and literature review of an under-recognised and heterogeneous condition SMC De Sousa, P Earls, AI McCormack Endocrinology, diabetes & metabolism case reports 2015 (1), 2015 | 43 | 2015 |
| Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma) N Lenders, A McCormack Pituitary 21 (2), 217-229, 2018 | 42 | 2018 |
| Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement MCS Boguszewski, CL Boguszewski, W Chemaililly, LE Cohen, ... European journal of endocrinology 186 (6), P35-P52, 2022 | 38 | 2022 |
| Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician’s questions J Trouillas, ML Jaffrain-Rea, A Vasiljevic, O Dekkers, V Popovic, ... Reviews in Endocrine and Metabolic Disorders 21, 243-251, 2020 | 37 | 2020 |
| Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients P Burman, J Trouillas, M Losa, A McCormack, S Petersenn, V Popovic, ... European journal of endocrinology 187 (4), 593-605, 2022 | 33 | 2022 |
| A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly PJ Trainer, JDC Newell-Price, J Ayuk, SJB Aylwin, A Rees, W Drake, ... European journal of endocrinology 179 (2), 97-108, 2018 | 32 | 2018 |
| Germline variants in familial pituitary tumour syndrome genes are common in young patients and families with additional endocrine tumours SM De Sousa, MJ McCabe, K Wu, T Roscioli, V Gayevskiy, K Brook, ... Eur J Endocrinol 176 (5), 635-644, 2017 | 32 | 2017 |
